Developing bioelectronic medicines for chronic diseases through a joint venture with GlaxoSmithKline
What is this project?
Galvani Bioelectronics is a joint venture between Verily and GlaxoSmithKline (GSK) enabling the research, development and commercialization of bioelectronic medicines.
How are you making it happen?
Galvani Bioelectronics integrates GSK’s drug discovery and development expertise and deep understanding of disease biology with our technical expertise in the miniaturization of low power electronics, device development, data analytics and software development for clinical application. Bioelectronic medicines are designed to treat disease by modulating electrical signals in peripheral nerves using miniature, implanted devices. They may provide an entirely new toolkit for control and reversal of disease, and could complement pharmaceutical and other therapies. Galvani’s initial work centers on establishing clinical proof of principle in inflammatory, metabolic and endocrine disorders and developing miniaturized, precise devices.